跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 2,701 条关于
“IMM2510/SYN-2510”
全部
2,701
临床试验
1,373
药物
833
机构
143
资讯
352
去年
Instil Bio's Partner ImmuneOnco Doses First Patient in NSCLC Trial with IMM2510/SYN-2510
去年
Instil Bio's PD-L1xVEGF Bispecific Antibody Shows Promise in NSCLC, Driving 48% Stock Surge
去年
Instil Bio and ImmuneOnco Advance PD-(L)1xVEGF Bispecific Antibody Clinical Development Strategy
8个月前
Instil Bio Terminates Licensing Agreement and Discontinues Lead Cancer Drug Development
7个月前
Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics in $38M Deal for Gut-Targeted Therapy
去年
Theriva Biologics Presents Phase 1b/2a Safety Data for SYN-004 in Hematopoietic Cell Transplant Recipients at ESCMID Global
上个月
Synaptiq Therapeutics Launches with Acquisition of SYN-001, a Phase II-Ready Small Molecule for 22q11.2 Deletion Syndrome
去年
Theriva Biologics' SYN-004 Shows Positive Safety Profile in Phase 1b/2a Trial for aGVHD Prevention
上个月
CND Life Sciences Secures Growth Financing Led by S-Curve Partners to Expand Syn-One Test Platform for Neurodegenerative Diagnostics
去年
Instil Bio Appoints Veteran Oncologist Jamie Freedman as Chief Medical Officer to Advance PD-L1xVEGF Bispecific
第 1 页,共 36 页
上一页
下一页